During the development of a novel therapeutic monoclonal antibody, neutralizumab, designed to treat plaque psoriasis, researchers transition from testing in animal models to clinical trials in humans.
Which of the following describes the primary objective of a Phase II clinical trial for neutralizumab?
To evaluate the safety, tolerability, and metabolic pathways of the antibody in a small group of healthy human volunteers.
To assess the clinical efficacy of the antibody and determine the optimal dosage in a medium-sized cohort of patients suffering from plaque psoriasis.
To compare the therapeutic effectiveness and safety of the antibody against existing standard-of-care treatments in a large, randomised patient population.
To monitor the long-term safety, rare side effects, and real-world performance of the antibody after it has been approved and licensed for general clinical use.